JP2009511589A - アリール−シクロプロピル誘導体のアスパルチルプロテアーゼ阻害剤を使用してアミロイドーシスを治療する方法 - Google Patents
アリール−シクロプロピル誘導体のアスパルチルプロテアーゼ阻害剤を使用してアミロイドーシスを治療する方法 Download PDFInfo
- Publication number
- JP2009511589A JP2009511589A JP2008535650A JP2008535650A JP2009511589A JP 2009511589 A JP2009511589 A JP 2009511589A JP 2008535650 A JP2008535650 A JP 2008535650A JP 2008535650 A JP2008535650 A JP 2008535650A JP 2009511589 A JP2009511589 A JP 2009511589A
- Authority
- JP
- Japan
- Prior art keywords
- difluorophenyl
- acetamide
- cyclopropylamino
- phenyl
- hydroxybutan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 308
- 206010002022 amyloidosis Diseases 0.000 title claims abstract description 55
- 239000003696 aspartic proteinase inhibitor Substances 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 361
- 101800001718 Amyloid-beta protein Proteins 0.000 claims abstract description 81
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 80
- 208000024891 symptom Diseases 0.000 claims abstract description 78
- 201000010099 disease Diseases 0.000 claims abstract description 52
- -1 3-benzyloxy-5-fluoro-benzyl Chemical group 0.000 claims description 433
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 claims description 137
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 claims description 137
- 239000000203 mixture Substances 0.000 claims description 116
- 150000003839 salts Chemical class 0.000 claims description 115
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 claims description 89
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 claims description 82
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 claims description 82
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 claims description 82
- 238000003776 cleavage reaction Methods 0.000 claims description 66
- 230000007017 scission Effects 0.000 claims description 66
- 125000000217 alkyl group Chemical group 0.000 claims description 56
- 230000000694 effects Effects 0.000 claims description 53
- 230000002401 inhibitory effect Effects 0.000 claims description 49
- 125000003118 aryl group Chemical group 0.000 claims description 45
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 44
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 39
- 229910052736 halogen Inorganic materials 0.000 claims description 39
- 230000005764 inhibitory process Effects 0.000 claims description 39
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 claims description 38
- 239000003112 inhibitor Substances 0.000 claims description 36
- 238000004519 manufacturing process Methods 0.000 claims description 36
- 210000004556 brain Anatomy 0.000 claims description 35
- 125000001072 heteroaryl group Chemical group 0.000 claims description 35
- 208000024827 Alzheimer disease Diseases 0.000 claims description 31
- 150000002367 halogens Chemical class 0.000 claims description 30
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 27
- 102000004580 Aspartic Acid Proteases Human genes 0.000 claims description 22
- 108010017640 Aspartic Acid Proteases Proteins 0.000 claims description 22
- 125000002619 bicyclic group Chemical group 0.000 claims description 17
- 230000035772 mutation Effects 0.000 claims description 17
- 125000003545 alkoxy group Chemical group 0.000 claims description 16
- 150000001413 amino acids Chemical class 0.000 claims description 16
- 206010012289 Dementia Diseases 0.000 claims description 15
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 15
- 229910052739 hydrogen Inorganic materials 0.000 claims description 14
- 229910052757 nitrogen Inorganic materials 0.000 claims description 14
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 13
- FJIMJPFTRLZRAJ-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-3-hydroxy-4-[[1-(3-pyrazol-1-ylphenyl)cyclopropyl]amino]butan-2-yl]acetamide Chemical compound C1CC1(C=1C=C(C=CC=1)N1N=CC=C1)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 FJIMJPFTRLZRAJ-UHFFFAOYSA-N 0.000 claims description 12
- 230000001404 mediated effect Effects 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 125000001188 haloalkyl group Chemical group 0.000 claims description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 9
- 239000002439 beta secretase inhibitor Substances 0.000 claims description 9
- IVEXILNYIOKCOY-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-4-[[1-[4-(2,2-dimethylpropyl)-1,3-thiazol-2-yl]cyclopropyl]amino]-3-hydroxybutan-2-yl]acetamide Chemical compound C1CC1(C=1SC=C(CC(C)(C)C)N=1)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 IVEXILNYIOKCOY-UHFFFAOYSA-N 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- 125000001424 substituent group Chemical group 0.000 claims description 9
- PMWZKFRZXLTHEJ-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-3-hydroxy-4-[[1-[3-(3,3,3-trifluoroprop-1-en-2-yl)phenyl]cyclopropyl]amino]butan-2-yl]acetamide Chemical compound C1CC1(C=1C=C(C=CC=1)C(=C)C(F)(F)F)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 PMWZKFRZXLTHEJ-UHFFFAOYSA-N 0.000 claims description 8
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 7
- VVZYJILCHBDRDY-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-3-hydroxy-4-[[1-[3-(2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)phenyl]cyclopropyl]amino]butan-2-yl]acetamide Chemical compound C1CC1(C=1C=C(C=CC=1)N1C2CC(OC2)C1)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 VVZYJILCHBDRDY-UHFFFAOYSA-N 0.000 claims description 7
- NGSPCALCYZCXEJ-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-4-[[1-[3-(1,4-dioxan-2-yl)phenyl]cyclopropyl]amino]-3-hydroxybutan-2-yl]acetamide Chemical compound C1CC1(C=1C=C(C=CC=1)C1OCCOC1)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 NGSPCALCYZCXEJ-UHFFFAOYSA-N 0.000 claims description 7
- 230000008901 benefit Effects 0.000 claims description 6
- 230000008859 change Effects 0.000 claims description 6
- 125000006317 cyclopropyl amino group Chemical group 0.000 claims description 6
- SIEADBCQDXYWBD-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-3-hydroxy-4-[[1-(3-pyrazol-1-ylphenyl)cyclopropyl]amino]butan-2-yl]-5-oxohexanamide Chemical compound C1CC1(C=1C=C(C=CC=1)N1N=CC=C1)NCC(O)C(NC(=O)CCCC(=O)C)CC1=CC(F)=CC(F)=C1 SIEADBCQDXYWBD-UHFFFAOYSA-N 0.000 claims description 6
- QGQLMQKKRGXLTO-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-4-[[1-[1-(2,2-dimethylpropyl)pyrazol-3-yl]cyclopropyl]amino]-3-hydroxybutan-2-yl]acetamide Chemical compound C1CC1(C1=NN(CC(C)(C)C)C=C1)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 QGQLMQKKRGXLTO-UHFFFAOYSA-N 0.000 claims description 6
- VGPRQBUXKLBDJH-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-4-[[1-[1-(2,2-dimethylpropyl)pyrazol-4-yl]cyclopropyl]amino]-3-hydroxybutan-2-yl]acetamide Chemical compound C1CC1(C1=CN(CC(C)(C)C)N=C1)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 VGPRQBUXKLBDJH-UHFFFAOYSA-N 0.000 claims description 6
- YEGCCSKZPHGALE-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-4-[[1-[4-(2,2-dimethylpropyl)thiophen-2-yl]cyclopropyl]amino]-3-hydroxybutan-2-yl]acetamide Chemical compound C1CC1(C=1SC=C(CC(C)(C)C)C=1)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 YEGCCSKZPHGALE-UHFFFAOYSA-N 0.000 claims description 6
- WETWCOGJYRYKDB-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-4-[[1-[5-(2,2-dimethylpropyl)pyridin-3-yl]cyclopropyl]amino]-3-hydroxybutan-2-yl]acetamide Chemical compound C1CC1(C=1C=C(CC(C)(C)C)C=NC=1)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 WETWCOGJYRYKDB-UHFFFAOYSA-N 0.000 claims description 6
- MVLKRGPDMFEWHT-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-3-hydroxy-4-[[1-(3-morpholin-4-ylphenyl)cyclopropyl]amino]butan-2-yl]acetamide Chemical compound C1CC1(C=1C=C(C=CC=1)N1CCOCC1)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 MVLKRGPDMFEWHT-UHFFFAOYSA-N 0.000 claims description 5
- KAVOLWRXJFPGTL-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-3-hydroxy-4-[[1-[3-(1,1,1-trifluoropropan-2-yl)phenyl]cyclopropyl]amino]butan-2-yl]acetamide Chemical compound FC(F)(F)C(C)C1=CC=CC(C2(CC2)NCC(O)C(CC=2C=C(F)C=C(F)C=2)NC(C)=O)=C1 KAVOLWRXJFPGTL-UHFFFAOYSA-N 0.000 claims description 5
- QJZPJRFZQVBYDT-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-3-hydroxy-4-[[1-[3-(1-methoxy-2-methylpropan-2-yl)phenyl]cyclopropyl]amino]butan-2-yl]acetamide Chemical compound COCC(C)(C)C1=CC=CC(C2(CC2)NCC(O)C(CC=2C=C(F)C=C(F)C=2)NC(C)=O)=C1 QJZPJRFZQVBYDT-UHFFFAOYSA-N 0.000 claims description 5
- DGXDCVZUXDMTLV-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-3-hydroxy-4-[[1-[3-(oxolan-2-yl)phenyl]cyclopropyl]amino]butan-2-yl]acetamide Chemical compound C1CC1(C=1C=C(C=CC=1)C1OCCC1)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 DGXDCVZUXDMTLV-UHFFFAOYSA-N 0.000 claims description 5
- RFBDMAJRPBJAJG-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-3-hydroxy-4-[[2-propan-2-yl-1-(3-pyrazol-1-ylphenyl)cyclopropyl]amino]butan-2-yl]acetamide Chemical compound CC(C)C1CC1(C=1C=C(C=CC=1)N1N=CC=C1)NCC(O)C(NC(C)=O)CC1=CC(F)=CC(F)=C1 RFBDMAJRPBJAJG-UHFFFAOYSA-N 0.000 claims description 5
- ZDWBVXDYSLNIIX-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-4-[[1-[1-(2,2-dimethylpropyl)triazol-4-yl]cyclopropyl]amino]-3-hydroxybutan-2-yl]acetamide Chemical compound C1CC1(C=1N=NN(CC(C)(C)C)C=1)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 ZDWBVXDYSLNIIX-UHFFFAOYSA-N 0.000 claims description 5
- OVWZHAXEKGLFGE-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-4-[[1-[2-(2,2-dimethylpropyl)-1,3-thiazol-4-yl]cyclopropyl]amino]-3-hydroxybutan-2-yl]acetamide Chemical compound C1CC1(C=1N=C(CC(C)(C)C)SC=1)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 OVWZHAXEKGLFGE-UHFFFAOYSA-N 0.000 claims description 5
- CGJKTEPHXZHNFQ-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-4-[[2-ethyl-1-(3-pyrazol-1-ylphenyl)cyclopropyl]amino]-3-hydroxybutan-2-yl]acetamide Chemical compound CCC1CC1(C=1C=C(C=CC=1)N1N=CC=C1)NCC(O)C(NC(C)=O)CC1=CC(F)=CC(F)=C1 CGJKTEPHXZHNFQ-UHFFFAOYSA-N 0.000 claims description 5
- SXBWNENFIQGMLK-UHFFFAOYSA-N n-[4-[[1-[3-(1,1-difluoro-2-methylpropan-2-yl)phenyl]cyclopropyl]amino]-1-(3,5-difluorophenyl)-3-hydroxybutan-2-yl]acetamide Chemical compound C1CC1(C=1C=C(C=CC=1)C(C)(C)C(F)F)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 SXBWNENFIQGMLK-UHFFFAOYSA-N 0.000 claims description 5
- JMXPNIPCZVRIMT-UHFFFAOYSA-N n-[4-[[1-[3-(1,2-difluoro-2-methylpropyl)phenyl]cyclopropyl]amino]-1-(3,5-difluorophenyl)-3-hydroxybutan-2-yl]acetamide Chemical compound C1CC1(C=1C=C(C=CC=1)C(F)C(C)(C)F)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 JMXPNIPCZVRIMT-UHFFFAOYSA-N 0.000 claims description 5
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims description 5
- 230000000284 resting effect Effects 0.000 claims description 5
- 125000004429 atom Chemical group 0.000 claims description 4
- JTLFPCGNZLJTAK-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-3-hydroxy-4-[[1-(3-thiomorpholin-4-ylphenyl)cyclopropyl]amino]butan-2-yl]acetamide Chemical compound C1CC1(C=1C=C(C=CC=1)N1CCSCC1)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 JTLFPCGNZLJTAK-UHFFFAOYSA-N 0.000 claims description 4
- MPYBDRDFSBFESO-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-3-hydroxy-4-[[1-[3-(2-methyloxolan-2-yl)phenyl]cyclopropyl]amino]butan-2-yl]acetamide Chemical compound C1CC1(C=1C=C(C=CC=1)C1(C)OCCC1)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 MPYBDRDFSBFESO-UHFFFAOYSA-N 0.000 claims description 4
- OPNYLVKDDWJTDR-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-3-hydroxy-4-[[1-[3-(oxan-2-yl)phenyl]cyclopropyl]amino]butan-2-yl]acetamide Chemical compound C1CC1(C=1C=C(C=CC=1)C1OCCCC1)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 OPNYLVKDDWJTDR-UHFFFAOYSA-N 0.000 claims description 4
- IROUFPLAOXNCIN-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-3-hydroxy-4-[[1-[3-(oxolan-3-yl)phenyl]cyclopropyl]amino]butan-2-yl]acetamide Chemical compound C1CC1(C=1C=C(C=CC=1)C1COCC1)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 IROUFPLAOXNCIN-UHFFFAOYSA-N 0.000 claims description 4
- MQWSLMZURQCBTK-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-4-[[1-[3-(1,3-dioxepan-5-yl)phenyl]cyclopropyl]amino]-3-hydroxybutan-2-yl]acetamide Chemical compound C1CC1(C=1C=C(C=CC=1)C1COCOCC1)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 MQWSLMZURQCBTK-UHFFFAOYSA-N 0.000 claims description 4
- RDDKTENUGJLKIL-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-4-[[1-[3-(1,3-dioxolan-4-yl)phenyl]cyclopropyl]amino]-3-hydroxybutan-2-yl]acetamide Chemical compound C1CC1(C=1C=C(C=CC=1)C1OCOC1)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 RDDKTENUGJLKIL-UHFFFAOYSA-N 0.000 claims description 4
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 claims description 3
- 125000005842 heteroatom Chemical group 0.000 claims description 3
- 239000002207 metabolite Substances 0.000 claims description 3
- PNWYSNDMUPTSHD-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-3-hydroxy-4-[(6-pyrazol-1-yl-6-bicyclo[3.1.0]hexanyl)amino]butan-2-yl]acetamide Chemical compound C12CCCC2C1(N1N=CC=C1)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 PNWYSNDMUPTSHD-UHFFFAOYSA-N 0.000 claims description 3
- KPMQZGRHZHWEMZ-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-3-hydroxy-4-[[1-(1-thiophen-3-yltriazol-4-yl)cyclopropyl]amino]butan-2-yl]acetamide Chemical compound C1CC1(C=1N=NN(C=1)C1=CSC=C1)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 KPMQZGRHZHWEMZ-UHFFFAOYSA-N 0.000 claims description 3
- OUEUEMKZZJYMIM-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-3-hydroxy-4-[[1-(3-pyrazol-1-ylphenyl)cyclopropyl]amino]butan-2-yl]-2-ethoxyacetamide Chemical compound C1CC1(C=1C=C(C=CC=1)N1N=CC=C1)NCC(O)C(NC(=O)COCC)CC1=CC(F)=CC(F)=C1 OUEUEMKZZJYMIM-UHFFFAOYSA-N 0.000 claims description 3
- KANWLHCDILVIRW-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-3-hydroxy-4-[[1-(3-pyrazol-1-ylphenyl)cyclopropyl]amino]butan-2-yl]-2-methoxyacetamide Chemical compound C1CC1(C=1C=C(C=CC=1)N1N=CC=C1)NCC(O)C(NC(=O)COC)CC1=CC(F)=CC(F)=C1 KANWLHCDILVIRW-UHFFFAOYSA-N 0.000 claims description 3
- ZDPPYXJEHKYKGE-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-3-hydroxy-4-[[1-(3-pyrazol-1-ylphenyl)cyclopropyl]amino]butan-2-yl]-2-phenylacetamide Chemical compound C=1C(F)=CC(F)=CC=1CC(NC(=O)CC=1C=CC=CC=1)C(O)CNC1(C=2C=C(C=CC=2)N2N=CC=C2)CC1 ZDPPYXJEHKYKGE-UHFFFAOYSA-N 0.000 claims description 3
- DMVPJCZBAVBQPC-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-3-hydroxy-4-[[1-(3-pyrazol-1-ylphenyl)cyclopropyl]amino]butan-2-yl]-4-oxopentanamide Chemical compound C1CC1(C=1C=C(C=CC=1)N1N=CC=C1)NCC(O)C(NC(=O)CCC(=O)C)CC1=CC(F)=CC(F)=C1 DMVPJCZBAVBQPC-UHFFFAOYSA-N 0.000 claims description 3
- PIVCHUBLEMUOKM-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-3-hydroxy-4-[[1-(3-sulfanylphenyl)cyclopropyl]amino]butan-2-yl]acetamide Chemical compound C1CC1(C=1C=C(S)C=CC=1)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 PIVCHUBLEMUOKM-UHFFFAOYSA-N 0.000 claims description 3
- IKMNHRLIPMFGAL-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-3-hydroxy-4-[[1-(4-pyrazol-1-ylthiophen-2-yl)cyclopropyl]amino]butan-2-yl]acetamide Chemical compound C1CC1(C=1SC=C(C=1)N1N=CC=C1)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 IKMNHRLIPMFGAL-UHFFFAOYSA-N 0.000 claims description 3
- JDXAAJLCRYSFNG-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-3-hydroxy-4-[[1-(5-pyrazol-1-ylpyridin-3-yl)cyclopropyl]amino]butan-2-yl]acetamide Chemical compound C1CC1(C=1C=C(C=NC=1)N1N=CC=C1)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 JDXAAJLCRYSFNG-UHFFFAOYSA-N 0.000 claims description 3
- WAEYCNOIECTQOQ-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-3-hydroxy-4-[[1-[3-(1,4-oxazepan-4-yl)phenyl]cyclopropyl]amino]butan-2-yl]acetamide Chemical compound C1CC1(C=1C=C(C=CC=1)N1CCOCCC1)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 WAEYCNOIECTQOQ-UHFFFAOYSA-N 0.000 claims description 3
- CNCUETDPNRPUSV-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-3-hydroxy-4-[[1-[3-(pyrazol-1-ylmethyl)phenyl]cyclopropyl]amino]butan-2-yl]acetamide Chemical compound C1CC1(C=1C=C(CN2N=CC=C2)C=CC=1)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 CNCUETDPNRPUSV-UHFFFAOYSA-N 0.000 claims description 3
- AANUSVIEJFJQNH-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-3-hydroxy-4-[[2-hydroxy-1-(3-pyrazol-1-ylphenyl)cyclopropyl]amino]butan-2-yl]acetamide Chemical compound C1C(O)C1(C=1C=C(C=CC=1)N1N=CC=C1)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 AANUSVIEJFJQNH-UHFFFAOYSA-N 0.000 claims description 3
- YSQIOKPLVZROBE-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-3-hydroxy-4-[[2-methyl-1-(3-pyrazol-1-ylphenyl)cyclopropyl]amino]butan-2-yl]acetamide Chemical compound CC1CC1(C=1C=C(C=CC=1)N1N=CC=C1)NCC(O)C(NC(C)=O)CC1=CC(F)=CC(F)=C1 YSQIOKPLVZROBE-UHFFFAOYSA-N 0.000 claims description 3
- IZGMSRGCRHWDAP-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-3-hydroxy-4-[[2-pyrazol-1-yl-1-(3-pyrazol-1-ylphenyl)cyclopropyl]amino]butan-2-yl]acetamide Chemical compound C1C(N2N=CC=C2)C1(C=1C=C(C=CC=1)N1N=CC=C1)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 IZGMSRGCRHWDAP-UHFFFAOYSA-N 0.000 claims description 3
- XUCPEEDRFNOSMV-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-3-hydroxy-4-[[6-(3-pyrazol-1-ylphenyl)-3-oxabicyclo[3.1.0]hexan-6-yl]amino]butan-2-yl]acetamide Chemical compound C12COCC2C1(C=1C=C(C=CC=1)N1N=CC=C1)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 XUCPEEDRFNOSMV-UHFFFAOYSA-N 0.000 claims description 3
- ZVMGGVCEJGGYGM-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-3-hydroxy-4-[[6-(3-pyrazol-1-ylphenyl)-6-bicyclo[3.1.0]hexanyl]amino]butan-2-yl]acetamide Chemical compound C12CCCC2C1(C=1C=C(C=CC=1)N1N=CC=C1)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 ZVMGGVCEJGGYGM-UHFFFAOYSA-N 0.000 claims description 3
- AIGWVGYYJFMMSE-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-4-[[1-[3-(2,2-dimethylpropyl)-5-hydroxyphenyl]cyclopropyl]amino]-3-hydroxybutan-2-yl]acetamide Chemical compound C1CC1(C=1C=C(CC(C)(C)C)C=C(O)C=1)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 AIGWVGYYJFMMSE-UHFFFAOYSA-N 0.000 claims description 3
- ZQCQQZFYWOCMQQ-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-4-[[1-[3-(2,2-dimethylpropyl)phenyl]cyclobutyl]amino]-3-hydroxybutan-2-yl]acetamide Chemical compound C1CCC1(C=1C=C(CC(C)(C)C)C=CC=1)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 ZQCQQZFYWOCMQQ-UHFFFAOYSA-N 0.000 claims description 3
- IMQXGQTZVYVTCM-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-4-[[1-[3-(3,5-difluorophenyl)phenyl]cyclopropyl]amino]-3-hydroxybutan-2-yl]acetamide Chemical compound C1CC1(C=1C=C(C=CC=1)C=1C=C(F)C=C(F)C=1)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 IMQXGQTZVYVTCM-UHFFFAOYSA-N 0.000 claims description 3
- JQMIMOHSWUTJON-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-4-[[1-[3-(3,6-dihydro-2h-pyran-2-yl)phenyl]cyclopropyl]amino]-3-hydroxybutan-2-yl]acetamide Chemical compound C1CC1(C=1C=C(C=CC=1)C1OCC=CC1)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 JQMIMOHSWUTJON-UHFFFAOYSA-N 0.000 claims description 3
- MIVSXFBYYKBPGG-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-4-[[1-[4-(3,3-dimethylbut-1-ynyl)thiophen-2-yl]cyclopropyl]amino]-3-hydroxybutan-2-yl]acetamide Chemical compound C1CC1(C=1SC=C(C=1)C#CC(C)(C)C)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 MIVSXFBYYKBPGG-UHFFFAOYSA-N 0.000 claims description 3
- QDQCHWIZBDKMNR-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-4-[[1-[4-(3,3-dimethylbutyl)thiophen-2-yl]cyclopropyl]amino]-3-hydroxybutan-2-yl]acetamide Chemical compound C1CC1(C=1SC=C(CCC(C)(C)C)C=1)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 QDQCHWIZBDKMNR-UHFFFAOYSA-N 0.000 claims description 3
- HKQXYIFUKGWWIW-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-4-[[1-[5-(2,2-dimethylpropyl)-1-hydroxy-2h-pyridin-3-yl]cyclopropyl]amino]-3-hydroxybutan-2-yl]acetamide Chemical compound C1CC1(C=1CN(O)C=C(CC(C)(C)C)C=1)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 HKQXYIFUKGWWIW-UHFFFAOYSA-N 0.000 claims description 3
- CZKXEGXIEYHWJE-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-4-[[1-[5-(2,2-dimethylpropyl)thiophen-2-yl]cyclopropyl]amino]-3-hydroxybutan-2-yl]acetamide Chemical compound C1CC1(C=1SC(CC(C)(C)C)=CC=1)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 CZKXEGXIEYHWJE-UHFFFAOYSA-N 0.000 claims description 3
- DDYVQZCCMNNVFX-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-4-[[2,2-dimethyl-1-(3-pyrazol-1-ylphenyl)cyclopropyl]amino]-3-hydroxybutan-2-yl]acetamide Chemical compound C1C(C)(C)C1(C=1C=C(C=CC=1)N1N=CC=C1)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 DDYVQZCCMNNVFX-UHFFFAOYSA-N 0.000 claims description 3
- QZJJBJQULIZPKJ-UHFFFAOYSA-N n-[4-[(2-benzyl-1-pyrazol-1-ylcyclopropyl)amino]-1-(3,5-difluorophenyl)-3-hydroxybutan-2-yl]acetamide Chemical compound C1C(CC=2C=CC=CC=2)C1(N1N=CC=C1)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 QZJJBJQULIZPKJ-UHFFFAOYSA-N 0.000 claims description 3
- VOSLCSAAEXCPJW-UHFFFAOYSA-N n-[4-[[1-(1-tert-butylpyrazol-3-yl)cyclopropyl]amino]-1-(3,5-difluorophenyl)-3-hydroxybutan-2-yl]acetamide Chemical compound C1CC1(C1=NN(C=C1)C(C)(C)C)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 VOSLCSAAEXCPJW-UHFFFAOYSA-N 0.000 claims description 3
- WEPJNZHCPOSLFU-UHFFFAOYSA-N n-[4-[[1-(1-tert-butylpyrazol-4-yl)cyclopropyl]amino]-1-(3,5-difluorophenyl)-3-hydroxybutan-2-yl]acetamide Chemical compound C1CC1(C1=CN(N=C1)C(C)(C)C)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 WEPJNZHCPOSLFU-UHFFFAOYSA-N 0.000 claims description 3
- NZGDAUFWGYKRKZ-UHFFFAOYSA-N n-[4-[[1-(3-cyclohexylphenyl)cyclopropyl]amino]-1-(3,5-difluorophenyl)-3-hydroxybutan-2-yl]acetamide Chemical compound C1CC1(C=1C=C(C=CC=1)C1CCCCC1)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 NZGDAUFWGYKRKZ-UHFFFAOYSA-N 0.000 claims description 3
- WYHKWULUJIUILV-UHFFFAOYSA-N n-[4-[[1-(3-cyclopentylphenyl)cyclopropyl]amino]-1-(3,5-difluorophenyl)-3-hydroxybutan-2-yl]acetamide Chemical compound C1CC1(C=1C=C(C=CC=1)C1CCCC1)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 WYHKWULUJIUILV-UHFFFAOYSA-N 0.000 claims description 3
- PJNDAZQEJOLDIW-UHFFFAOYSA-N n-[4-[[1-(3-tert-butylphenyl)cyclopropyl]amino]-1-(3,5-difluorophenyl)-3-hydroxybutan-2-yl]acetamide Chemical compound C1CC1(C=1C=C(C=CC=1)C(C)(C)C)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 PJNDAZQEJOLDIW-UHFFFAOYSA-N 0.000 claims description 3
- BOZUJJDDLKJGKX-UHFFFAOYSA-N n-[4-[[1-(5-tert-butylthiophen-3-yl)cyclopropyl]amino]-1-(3,5-difluorophenyl)-3-hydroxybutan-2-yl]acetamide Chemical compound C1CC1(C=1C=C(SC=1)C(C)(C)C)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 BOZUJJDDLKJGKX-UHFFFAOYSA-N 0.000 claims description 3
- SQQKQGZDGDICAQ-UHFFFAOYSA-N n-[4-[[6-(3-bromophenyl)-6-bicyclo[3.1.0]hexanyl]amino]-1-(3,5-difluorophenyl)-3-hydroxybutan-2-yl]acetamide Chemical compound C12CCCC2C1(C=1C=C(Br)C=CC=1)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 SQQKQGZDGDICAQ-UHFFFAOYSA-N 0.000 claims description 3
- LNDBIGGNAVZCJB-UHFFFAOYSA-N n-[4-[[6-(4-tert-butylpyridin-2-yl)-6-bicyclo[3.1.0]hexanyl]amino]-1-(3,5-difluorophenyl)-3-hydroxybutan-2-yl]acetamide Chemical compound C12CCCC2C1(C=1N=CC=C(C=1)C(C)(C)C)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 LNDBIGGNAVZCJB-UHFFFAOYSA-N 0.000 claims description 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- YNAXKCRTFJQYDT-UHFFFAOYSA-N 2-hydroxy-5-methylbenzamide Chemical compound CC1=CC=C(O)C(C(N)=O)=C1 YNAXKCRTFJQYDT-UHFFFAOYSA-N 0.000 claims description 2
- 125000006291 3-hydroxybenzyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(=C1[H])C([H])([H])* 0.000 claims description 2
- 125000003143 4-hydroxybenzyl group Chemical group [H]C([*])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 claims description 2
- ZOCZHKZWIYSWJT-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-3-hydroxy-4-[[1-[3-(3-oxomorpholin-4-yl)phenyl]cyclopropyl]amino]butan-2-yl]acetamide Chemical compound C1CC1(C=1C=C(C=CC=1)N1C(COCC1)=O)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 ZOCZHKZWIYSWJT-UHFFFAOYSA-N 0.000 claims description 2
- VSPUEQIYSUJPJH-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-3-hydroxy-4-[[1-[3-(5-methylthiophen-2-yl)phenyl]cyclopropyl]amino]butan-2-yl]acetamide Chemical compound C1CC1(C=1C=C(C=CC=1)C=1SC(C)=CC=1)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 VSPUEQIYSUJPJH-UHFFFAOYSA-N 0.000 claims description 2
- ZWUYVLYQVJVUAE-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-3-hydroxy-4-[[1-[3-(5-methylthiophen-3-yl)phenyl]cyclopropyl]amino]butan-2-yl]acetamide Chemical compound C1CC1(C=1C=C(C=CC=1)C=1C=C(C)SC=1)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 ZWUYVLYQVJVUAE-UHFFFAOYSA-N 0.000 claims description 2
- IRYPDHDPDDSJAA-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-3-hydroxy-4-[[1-[4-(pyrazol-1-ylmethyl)thiophen-2-yl]cyclopropyl]amino]butan-2-yl]acetamide Chemical compound C1CC1(C=1SC=C(CN2N=CC=C2)C=1)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 IRYPDHDPDDSJAA-UHFFFAOYSA-N 0.000 claims description 2
- FSGWAITTXZEQNG-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-3-hydroxy-4-[[2-(2-hydroxyethyl)-1-(3-pyrazol-1-ylphenyl)cyclopropyl]amino]butan-2-yl]acetamide Chemical compound C1C(CCO)C1(C=1C=C(C=CC=1)N1N=CC=C1)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 FSGWAITTXZEQNG-UHFFFAOYSA-N 0.000 claims description 2
- CCULZVPNHUEQJZ-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-3-hydroxy-4-[[2-(hydroxymethyl)-1-(3-pyrazol-1-ylphenyl)cyclopropyl]amino]butan-2-yl]acetamide Chemical compound C1C(CO)C1(C=1C=C(C=CC=1)N1N=CC=C1)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 CCULZVPNHUEQJZ-UHFFFAOYSA-N 0.000 claims description 2
- POYTZWORRGLCCM-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-4-[[1-[3-(3,6-dihydro-2h-pyran-6-yl)phenyl]cyclopropyl]amino]-3-hydroxybutan-2-yl]acetamide Chemical compound C1CC1(C=1C=C(C=CC=1)C1C=CCCO1)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 POYTZWORRGLCCM-UHFFFAOYSA-N 0.000 claims description 2
- HBESBLSFMMMSSP-UHFFFAOYSA-N n-[4-[[1-[3-(3-azabicyclo[2.2.1]heptan-3-yl)phenyl]cyclopropyl]amino]-1-(3,5-difluorophenyl)-3-hydroxybutan-2-yl]acetamide Chemical compound C1CC1(C=1C=C(C=CC=1)N1C2CCC(C2)C1)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 HBESBLSFMMMSSP-UHFFFAOYSA-N 0.000 claims description 2
- IXFUONUONXTQGK-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-4-[[1-(2,6-difluoro-3-pyrazol-1-ylphenyl)cyclopropyl]amino]-3-hydroxybutan-2-yl]acetamide Chemical compound C1CC1(C=1C(=C(C=CC=1F)N1N=CC=C1)F)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 IXFUONUONXTQGK-UHFFFAOYSA-N 0.000 claims 2
- 125000006284 3-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(F)=C1[H])C([H])([H])* 0.000 claims 1
- CDRYJXDHQWBBGU-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-3-hydroxy-4-[[1-(3-pyrazol-1-ylphenyl)cyclopropyl]amino]butan-2-yl]-5-oxopyrrolidine-2-carboxamide Chemical compound C=1C(F)=CC(F)=CC=1CC(NC(=O)C1NC(=O)CC1)C(O)CNC1(C=2C=C(C=CC=2)N2N=CC=C2)CC1 CDRYJXDHQWBBGU-UHFFFAOYSA-N 0.000 claims 1
- 208000035475 disorder Diseases 0.000 abstract description 28
- 230000008021 deposition Effects 0.000 abstract description 6
- 230000002159 abnormal effect Effects 0.000 abstract description 5
- 108090000623 proteins and genes Proteins 0.000 abstract description 2
- 102000004169 proteins and genes Human genes 0.000 abstract description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 162
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 127
- 230000014759 maintenance of location Effects 0.000 description 105
- 239000000243 solution Substances 0.000 description 103
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 81
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 75
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 75
- 238000004128 high performance liquid chromatography Methods 0.000 description 62
- 238000000132 electrospray ionisation Methods 0.000 description 59
- 238000003756 stirring Methods 0.000 description 59
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 51
- 239000000758 substrate Substances 0.000 description 48
- 235000019439 ethyl acetate Nutrition 0.000 description 47
- 239000011541 reaction mixture Substances 0.000 description 46
- 238000003556 assay Methods 0.000 description 45
- 238000011282 treatment Methods 0.000 description 41
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 40
- 239000003480 eluent Substances 0.000 description 37
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 36
- 210000004027 cell Anatomy 0.000 description 36
- 101001017818 Homo sapiens ATP-dependent translocase ABCB1 Proteins 0.000 description 35
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 35
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 35
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 34
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 33
- 239000003921 oil Substances 0.000 description 32
- 235000019198 oils Nutrition 0.000 description 32
- 239000002552 dosage form Substances 0.000 description 31
- 239000008241 heterogeneous mixture Substances 0.000 description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 31
- 229940088598 enzyme Drugs 0.000 description 26
- 102000004190 Enzymes Human genes 0.000 description 25
- 108090000790 Enzymes Proteins 0.000 description 25
- 239000000284 extract Substances 0.000 description 25
- 239000000047 product Substances 0.000 description 25
- 238000006243 chemical reaction Methods 0.000 description 23
- 108090000765 processed proteins & peptides Proteins 0.000 description 23
- 239000000741 silica gel Substances 0.000 description 23
- 229910002027 silica gel Inorganic materials 0.000 description 23
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 22
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical group CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 22
- 238000001514 detection method Methods 0.000 description 22
- GZEROYVZVZFORY-UHFFFAOYSA-N 1-(3-pyrazol-1-ylphenyl)cyclopropan-1-amine Chemical compound C=1C=CC(N2N=CC=C2)=CC=1C1(N)CC1 GZEROYVZVZFORY-UHFFFAOYSA-N 0.000 description 20
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 20
- 235000019341 magnesium sulphate Nutrition 0.000 description 20
- 238000012360 testing method Methods 0.000 description 20
- 238000002560 therapeutic procedure Methods 0.000 description 20
- 238000010898 silica gel chromatography Methods 0.000 description 19
- 150000001412 amines Chemical class 0.000 description 18
- VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 17
- 241001465754 Metazoa Species 0.000 description 16
- 239000011734 sodium Substances 0.000 description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 239000000725 suspension Substances 0.000 description 15
- 239000002775 capsule Substances 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 14
- 239000013543 active substance Substances 0.000 description 13
- 238000010255 intramuscular injection Methods 0.000 description 13
- 239000007927 intramuscular injection Substances 0.000 description 13
- 238000001990 intravenous administration Methods 0.000 description 13
- 230000035699 permeability Effects 0.000 description 13
- 229920006395 saturated elastomer Polymers 0.000 description 13
- 238000005160 1H NMR spectroscopy Methods 0.000 description 12
- 0 CCC(*)(*(*)CC(*)C(C)*(C)*)N Chemical compound CCC(*)(*(*)CC(*)C(C)*(C)*)N 0.000 description 12
- 229940024606 amino acid Drugs 0.000 description 12
- 230000008499 blood brain barrier function Effects 0.000 description 12
- 210000001218 blood-brain barrier Anatomy 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 238000011534 incubation Methods 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 239000006186 oral dosage form Substances 0.000 description 12
- 239000012074 organic phase Substances 0.000 description 12
- 102100021257 Beta-secretase 1 Human genes 0.000 description 11
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 11
- 125000004122 cyclic group Chemical group 0.000 description 11
- 239000001257 hydrogen Substances 0.000 description 11
- 238000003018 immunoassay Methods 0.000 description 11
- 238000002953 preparative HPLC Methods 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 230000003993 interaction Effects 0.000 description 10
- 239000010410 layer Substances 0.000 description 10
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 9
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 9
- 125000006239 protecting group Chemical group 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- 239000003981 vehicle Substances 0.000 description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- STXAVEHFKAXGOX-UHFFFAOYSA-N 3-bromobenzonitrile Chemical compound BrC1=CC=CC(C#N)=C1 STXAVEHFKAXGOX-UHFFFAOYSA-N 0.000 description 8
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 8
- 210000005013 brain tissue Anatomy 0.000 description 8
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 8
- 239000003937 drug carrier Substances 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 238000012856 packing Methods 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 7
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 7
- 101000894895 Homo sapiens Beta-secretase 1 Proteins 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000000908 ammonium hydroxide Substances 0.000 description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- VGIRNWJSIRVFRT-UHFFFAOYSA-N 2',7'-difluorofluorescein Chemical compound OC(=O)C1=CC=CC=C1C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21 VGIRNWJSIRVFRT-UHFFFAOYSA-N 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- 239000007943 implant Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- TYPXRTVFFHZQRD-UHFFFAOYSA-N 3-(1,2-difluoro-2-methylpropyl)benzonitrile Chemical compound CC(C)(F)C(F)C1=CC=CC(C#N)=C1 TYPXRTVFFHZQRD-UHFFFAOYSA-N 0.000 description 5
- SUYRHLUETUZLEL-UHFFFAOYSA-N 3-(2,3-dihydrofuran-3-yl)benzonitrile Chemical compound N#CC1=CC=CC(C2C=COC2)=C1 SUYRHLUETUZLEL-UHFFFAOYSA-N 0.000 description 5
- 208000037259 Amyloid Plaque Diseases 0.000 description 5
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 5
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 5
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 5
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 5
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 5
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 5
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 description 5
- 125000004663 dialkyl amino group Chemical group 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- HWZKQIRJZPOEQF-UHFFFAOYSA-N n-acetyl-n-methoxyacetamide Chemical compound CON(C(C)=O)C(C)=O HWZKQIRJZPOEQF-UHFFFAOYSA-N 0.000 description 5
- 230000000508 neurotrophic effect Effects 0.000 description 5
- 150000002825 nitriles Chemical class 0.000 description 5
- 239000006201 parenteral dosage form Substances 0.000 description 5
- YPJUNDFVDDCYIH-UHFFFAOYSA-N perfluorobutyric acid Chemical compound OC(=O)C(F)(F)C(F)(F)C(F)(F)F YPJUNDFVDDCYIH-UHFFFAOYSA-N 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 239000012730 sustained-release form Substances 0.000 description 5
- 230000009261 transgenic effect Effects 0.000 description 5
- ZTSGSVKMSGIDPA-UHFFFAOYSA-N 1-[3-(1,1-difluoro-2-methylpropan-2-yl)phenyl]cyclopropan-1-amine Chemical compound FC(F)C(C)(C)C1=CC=CC(C2(N)CC2)=C1 ZTSGSVKMSGIDPA-UHFFFAOYSA-N 0.000 description 4
- CRWBZJYXHMPUDN-UHFFFAOYSA-N 1-[3-(oxan-2-yl)phenyl]cyclopropan-1-amine Chemical compound C=1C=CC(C2OCCCC2)=CC=1C1(N)CC1 CRWBZJYXHMPUDN-UHFFFAOYSA-N 0.000 description 4
- YAVNZUJOXOYJOW-UHFFFAOYSA-N 3-(1,1-difluoro-2-methylpropan-2-yl)benzonitrile Chemical compound FC(F)C(C)(C)C1=CC=CC(C#N)=C1 YAVNZUJOXOYJOW-UHFFFAOYSA-N 0.000 description 4
- VVKHHIBYHQUXMP-UHFFFAOYSA-N 3-(1-hydroxy-2-methylpropan-2-yl)benzonitrile Chemical compound OCC(C)(C)C1=CC=CC(C#N)=C1 VVKHHIBYHQUXMP-UHFFFAOYSA-N 0.000 description 4
- GIQWTVUYTJJUFY-UHFFFAOYSA-N 3-(2,5-dihydrofuran-2-yl)benzonitrile Chemical compound N#CC1=CC=CC(C2C=CCO2)=C1 GIQWTVUYTJJUFY-UHFFFAOYSA-N 0.000 description 4
- IEQCBYFZUOLVNR-UHFFFAOYSA-N 3-[2-(iodomethyl)oxolan-2-yl]benzonitrile Chemical compound C=1C=CC(C#N)=CC=1C1(CI)CCCO1 IEQCBYFZUOLVNR-UHFFFAOYSA-N 0.000 description 4
- AIXWZTXMXRWFNQ-UHFFFAOYSA-N 3-amino-1-[[1-[3-(1,2-difluoro-2-methylpropyl)phenyl]cyclopropyl]amino]-4-(3,5-difluorophenyl)butan-2-ol Chemical compound CC(C)(F)C(F)C1=CC=CC(C2(CC2)NCC(O)C(N)CC=2C=C(F)C=C(F)C=2)=C1 AIXWZTXMXRWFNQ-UHFFFAOYSA-N 0.000 description 4
- KKHRYAXQVKSSDQ-UHFFFAOYSA-N 3-amino-4-(3,5-difluorophenyl)-1-[[1-(3-pyrazol-1-ylphenyl)cyclopropyl]amino]butan-2-ol Chemical compound C1CC1(C=1C=C(C=CC=1)N1N=CC=C1)NCC(O)C(N)CC1=CC(F)=CC(F)=C1 KKHRYAXQVKSSDQ-UHFFFAOYSA-N 0.000 description 4
- UNGFTAHSCBPMJA-UHFFFAOYSA-N 3-amino-4-(3,5-difluorophenyl)-1-[[2-ethyl-1-(3-pyrazol-1-ylphenyl)cyclopropyl]amino]butan-2-ol Chemical compound CCC1CC1(C=1C=C(C=CC=1)N1N=CC=C1)NCC(O)C(N)CC1=CC(F)=CC(F)=C1 UNGFTAHSCBPMJA-UHFFFAOYSA-N 0.000 description 4
- 101710150192 Beta-secretase 1 Proteins 0.000 description 4
- 201000010374 Down Syndrome Diseases 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 125000005236 alkanoylamino group Chemical group 0.000 description 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 4
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 4
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 4
- 125000004414 alkyl thio group Chemical group 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 125000004103 aminoalkyl group Chemical group 0.000 description 4
- 230000006933 amyloid-beta aggregation Effects 0.000 description 4
- 239000002260 anti-inflammatory agent Substances 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 239000000544 cholinesterase inhibitor Substances 0.000 description 4
- 230000001149 cognitive effect Effects 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 239000003540 gamma secretase inhibitor Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
- 235000021317 phosphate Nutrition 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000007909 solid dosage form Substances 0.000 description 4
- 239000012258 stirred mixture Substances 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 238000011200 topical administration Methods 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- RIHBTUWMJQKYOV-UHFFFAOYSA-N 1-(3-morpholin-4-ylphenyl)cyclopropan-1-amine Chemical compound C=1C=CC(N2CCOCC2)=CC=1C1(N)CC1 RIHBTUWMJQKYOV-UHFFFAOYSA-N 0.000 description 3
- MMNOLIJIEKQIQS-UHFFFAOYSA-N 1-(5-tert-butyl-1,3-oxazol-2-yl)cyclopropan-1-amine Chemical compound O1C(C(C)(C)C)=CN=C1C1(N)CC1 MMNOLIJIEKQIQS-UHFFFAOYSA-N 0.000 description 3
- WKEWQCWLRMHVKG-UHFFFAOYSA-N 1-[2-(2,2-dimethylpropyl)-1,3-thiazol-4-yl]cyclopropan-1-amine Chemical compound S1C(CC(C)(C)C)=NC(C2(N)CC2)=C1 WKEWQCWLRMHVKG-UHFFFAOYSA-N 0.000 description 3
- MOAUDQOGYBFAEA-UHFFFAOYSA-N 1-[3-(1,3-dioxepan-5-yl)phenyl]cyclopropan-1-amine Chemical compound C=1C=CC(C2COCOCC2)=CC=1C1(N)CC1 MOAUDQOGYBFAEA-UHFFFAOYSA-N 0.000 description 3
- PXDADNAPUVHQPX-UHFFFAOYSA-N 1-[3-(1,3-dioxolan-4-yl)phenyl]cyclopropan-1-amine Chemical compound C=1C=CC(C2OCOC2)=CC=1C1(N)CC1 PXDADNAPUVHQPX-UHFFFAOYSA-N 0.000 description 3
- PSMQNLQRQYXXMY-UHFFFAOYSA-N 1-[3-(1,4-dioxan-2-yl)phenyl]cyclopropan-1-amine Chemical compound C=1C=CC(C2OCCOC2)=CC=1C1(N)CC1 PSMQNLQRQYXXMY-UHFFFAOYSA-N 0.000 description 3
- JOHUIRVWDYKCTB-UHFFFAOYSA-N 1-[3-(1-methoxy-2-methylpropan-2-yl)phenyl]cyclopropan-1-amine Chemical compound COCC(C)(C)C1=CC=CC(C2(N)CC2)=C1 JOHUIRVWDYKCTB-UHFFFAOYSA-N 0.000 description 3
- BCADRFIWZMZSLO-UHFFFAOYSA-N 1-[3-(2-methyloxolan-2-yl)phenyl]cyclopropan-1-amine Chemical compound C=1C=CC(C2(N)CC2)=CC=1C1(C)CCCO1 BCADRFIWZMZSLO-UHFFFAOYSA-N 0.000 description 3
- XCGJZCKAXPYEPJ-UHFFFAOYSA-N 1-[3-(oxolan-2-yl)phenyl]cyclopropan-1-amine Chemical compound C=1C=CC(C2OCCC2)=CC=1C1(N)CC1 XCGJZCKAXPYEPJ-UHFFFAOYSA-N 0.000 description 3
- ACZFMDFLUWXYPF-UHFFFAOYSA-N 1-[3-(oxolan-3-yl)phenyl]cyclopropan-1-amine Chemical compound C=1C=CC(C2COCC2)=CC=1C1(N)CC1 ACZFMDFLUWXYPF-UHFFFAOYSA-N 0.000 description 3
- XJYHAITWENOGSH-UHFFFAOYSA-N 1-[4-(2,2-dimethylpropyl)-1,3-thiazol-2-yl]cyclopropan-1-amine Chemical compound CC(C)(C)CC1=CSC(C2(N)CC2)=N1 XJYHAITWENOGSH-UHFFFAOYSA-N 0.000 description 3
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- UZZNJUVDBGBVLQ-UHFFFAOYSA-N 2-(2,2-dimethylpropyl)-1,3-thiazole-4-carbonitrile Chemical compound CC(C)(C)CC1=NC(C#N)=CS1 UZZNJUVDBGBVLQ-UHFFFAOYSA-N 0.000 description 3
- RPYGNUJSGOMETM-UHFFFAOYSA-N 2-(3-cyanophenyl)-2-methylpropanoic acid Chemical compound OC(=O)C(C)(C)C1=CC=CC(C#N)=C1 RPYGNUJSGOMETM-UHFFFAOYSA-N 0.000 description 3
- NARWPYRALODUDG-UHFFFAOYSA-N 2-(4-bromopent-4-enoxy)oxane Chemical compound BrC(=C)CCCOC1CCCCO1 NARWPYRALODUDG-UHFFFAOYSA-N 0.000 description 3
- VTOJIHOHIGHWJD-UHFFFAOYSA-N 2-ethyl-1-(3-pyrazol-1-ylphenyl)cyclopropan-1-amine Chemical compound CCC1CC1(N)C1=CC=CC(N2N=CC=C2)=C1 VTOJIHOHIGHWJD-UHFFFAOYSA-N 0.000 description 3
- WRPOVQMOOHJZAU-UHFFFAOYSA-N 2-propan-2-yl-1-(3-pyrazol-1-ylphenyl)cyclopropan-1-amine Chemical compound CC(C)C1CC1(N)C1=CC=CC(N2N=CC=C2)=C1 WRPOVQMOOHJZAU-UHFFFAOYSA-N 0.000 description 3
- 125000006288 3,5-difluorobenzyl group Chemical group [H]C1=C(F)C([H])=C(C([H])=C1F)C([H])([H])* 0.000 description 3
- DTBZIKXQEKAHFC-UHFFFAOYSA-N 3-(1,2-dihydroxyethyl)benzonitrile Chemical compound OCC(O)C1=CC=CC(C#N)=C1 DTBZIKXQEKAHFC-UHFFFAOYSA-N 0.000 description 3
- LZVSTHFEPRKVSG-UHFFFAOYSA-N 3-(1,3-dioxepan-5-yl)benzonitrile Chemical compound N#CC1=CC=CC(C2COCOCC2)=C1 LZVSTHFEPRKVSG-UHFFFAOYSA-N 0.000 description 3
- KUJSYZLXXPZGAH-UHFFFAOYSA-N 3-(1-methoxy-2-methylpropan-2-yl)benzonitrile Chemical compound COCC(C)(C)C1=CC=CC(C#N)=C1 KUJSYZLXXPZGAH-UHFFFAOYSA-N 0.000 description 3
- ZPNURJVKYAKTDP-UHFFFAOYSA-N 3-(2-methyl-1-oxopropan-2-yl)benzonitrile Chemical compound O=CC(C)(C)C1=CC=CC(C#N)=C1 ZPNURJVKYAKTDP-UHFFFAOYSA-N 0.000 description 3
- OWCRMCDGHXJHIT-UHFFFAOYSA-N 3-(2-methyloxolan-2-yl)benzonitrile Chemical compound C=1C=CC(C#N)=CC=1C1(C)CCCO1 OWCRMCDGHXJHIT-UHFFFAOYSA-N 0.000 description 3
- GEAXLFYEVDJLPG-UHFFFAOYSA-N 3-(2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)benzonitrile Chemical compound N#CC1=CC=CC(N2C3CC(OC3)C2)=C1 GEAXLFYEVDJLPG-UHFFFAOYSA-N 0.000 description 3
- SQNUGCVXFYQDMY-UHFFFAOYSA-N 3-(4,5-dihydro-1,3-dioxepin-5-yl)benzonitrile Chemical compound N#CC1=CC=CC(C2C=COCOC2)=C1 SQNUGCVXFYQDMY-UHFFFAOYSA-N 0.000 description 3
- DPDUBBJRNHFYMM-UHFFFAOYSA-N 3-(5-hydroxypent-1-en-2-yl)benzonitrile Chemical compound OCCCC(=C)C1=CC=CC(C#N)=C1 DPDUBBJRNHFYMM-UHFFFAOYSA-N 0.000 description 3
- NTOCFEBXCBTXFB-UHFFFAOYSA-N 3-(oxolan-2-yl)benzonitrile Chemical compound N#CC1=CC=CC(C2OCCC2)=C1 NTOCFEBXCBTXFB-UHFFFAOYSA-N 0.000 description 3
- SSSCEFGNPAHXQZ-UHFFFAOYSA-N 3-(oxolan-3-yl)benzonitrile Chemical compound N#CC1=CC=CC(C2COCC2)=C1 SSSCEFGNPAHXQZ-UHFFFAOYSA-N 0.000 description 3
- HMNMVJBQWJKFRH-UHFFFAOYSA-N 3-amino-4-(3,5-difluorophenyl)-1-[[1-[2-(2,2-dimethylpropyl)-1,3-thiazol-4-yl]cyclopropyl]amino]butan-2-ol Chemical compound S1C(CC(C)(C)C)=NC(C2(CC2)NCC(O)C(N)CC=2C=C(F)C=C(F)C=2)=C1 HMNMVJBQWJKFRH-UHFFFAOYSA-N 0.000 description 3
- XJWPLAZZPJKUIN-UHFFFAOYSA-N 3-amino-4-(3,5-difluorophenyl)-1-[[2-propan-2-yl-1-(3-pyrazol-1-ylphenyl)cyclopropyl]amino]butan-2-ol Chemical compound CC(C)C1CC1(C=1C=C(C=CC=1)N1N=CC=C1)NCC(O)C(N)CC1=CC(F)=CC(F)=C1 XJWPLAZZPJKUIN-UHFFFAOYSA-N 0.000 description 3
- KLZKYUMVLIQOFX-UHFFFAOYSA-N 3-pyrazol-1-ylbenzonitrile Chemical compound N#CC1=CC=CC(N2N=CC=C2)=C1 KLZKYUMVLIQOFX-UHFFFAOYSA-N 0.000 description 3
- HWLQDAFYWZVFTG-UHFFFAOYSA-N 4-(2,2-dimethylpropyl)-1,3-thiazole Chemical compound CC(C)(C)CC1=CSC=N1 HWLQDAFYWZVFTG-UHFFFAOYSA-N 0.000 description 3
- DUIAINUTWPOXDY-UHFFFAOYSA-N 4-(2,2-dimethylpropyl)-1,3-thiazole-2-carbaldehyde Chemical compound CC(C)(C)CC1=CSC(C=O)=N1 DUIAINUTWPOXDY-UHFFFAOYSA-N 0.000 description 3
- KZOULUJTHGHIFL-UHFFFAOYSA-N 4-(2,2-dimethylpropyl)-1,3-thiazole-2-carbonitrile Chemical compound CC(C)(C)CC1=CSC(C#N)=N1 KZOULUJTHGHIFL-UHFFFAOYSA-N 0.000 description 3
- FSXDHPWMOQOHGL-UHFFFAOYSA-N 4-bromo-2-(2,2-dimethylpropyl)-1,3-thiazole Chemical compound CC(C)(C)CC1=NC(Br)=CS1 FSXDHPWMOQOHGL-UHFFFAOYSA-N 0.000 description 3
- FDTDLMYTGDRZHM-UHFFFAOYSA-N 4-bromopent-4-en-1-ol Chemical compound OCCCC(Br)=C FDTDLMYTGDRZHM-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 3
- RKOTXQYWCBGZLP-UHFFFAOYSA-N N-[(2,4-difluorophenyl)methyl]-2-ethyl-9-hydroxy-3-methoxy-1,8-dioxospiro[3H-pyrido[1,2-a]pyrazine-4,3'-oxolane]-7-carboxamide Chemical compound CCN1C(OC)C2(CCOC2)N2C=C(C(=O)NCC3=C(F)C=C(F)C=C3)C(=O)C(O)=C2C1=O RKOTXQYWCBGZLP-UHFFFAOYSA-N 0.000 description 3
- RCMWEKYTXXCYQK-UHFFFAOYSA-N N-[[4-(2,2-dimethylpropyl)-1,3-thiazol-2-yl]methylidene]hydroxylamine Chemical compound CC(C)(C)CC1=CSC(C=NO)=N1 RCMWEKYTXXCYQK-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108010090804 Streptavidin Proteins 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000011149 active material Substances 0.000 description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 3
- 229960003529 diazepam Drugs 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000006911 enzymatic reaction Methods 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 3
- 125000002883 imidazolyl group Chemical group 0.000 description 3
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 3
- 229960001936 indinavir Drugs 0.000 description 3
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 230000018791 negative regulation of catalytic activity Effects 0.000 description 3
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 125000002971 oxazolyl group Chemical group 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 125000003373 pyrazinyl group Chemical group 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 229960001685 tacrine Drugs 0.000 description 3
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 3
- 125000001113 thiadiazolyl group Chemical group 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- LHDCBBUZBXMAAT-UHFFFAOYSA-N 1-[3-(1,2-difluoro-2-methylpropyl)phenyl]cyclopropan-1-amine Chemical compound CC(C)(F)C(F)C1=CC=CC(C2(N)CC2)=C1 LHDCBBUZBXMAAT-UHFFFAOYSA-N 0.000 description 2
- QAFUZWXHGNAVFS-UHFFFAOYSA-N 1-[3-(3,3,3-trifluoroprop-1-en-2-yl)phenyl]cyclopropan-1-amine Chemical compound C=1C=CC(C(=C)C(F)(F)F)=CC=1C1(N)CC1 QAFUZWXHGNAVFS-UHFFFAOYSA-N 0.000 description 2
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 2
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 2
- ARGCQEVBJHPOGB-UHFFFAOYSA-N 2,5-dihydrofuran Chemical compound C1OCC=C1 ARGCQEVBJHPOGB-UHFFFAOYSA-N 0.000 description 2
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 2
- 125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 2
- SHTDECNPYXCCGL-UHFFFAOYSA-N 3-(1,3-dioxolan-4-yl)benzonitrile Chemical compound N#CC1=CC=CC(C2OCOC2)=C1 SHTDECNPYXCCGL-UHFFFAOYSA-N 0.000 description 2
- PQTZKCKLJMGAEN-UHFFFAOYSA-N 3-(1,4-dioxan-2-yl)benzonitrile Chemical compound N#CC1=CC=CC(C2OCCOC2)=C1 PQTZKCKLJMGAEN-UHFFFAOYSA-N 0.000 description 2
- HGLRSCJHJYNZRS-UHFFFAOYSA-N 3-(2,3-dihydro-1,4-dioxin-5-yl)benzonitrile Chemical compound N#CC1=CC=CC(C=2OCCOC=2)=C1 HGLRSCJHJYNZRS-UHFFFAOYSA-N 0.000 description 2
- YOGURZZJHNQVAS-UHFFFAOYSA-N 3-(3,3,3-trifluoroprop-1-en-2-yl)benzonitrile Chemical compound FC(F)(F)C(=C)C1=CC=CC(C#N)=C1 YOGURZZJHNQVAS-UHFFFAOYSA-N 0.000 description 2
- OSKOSPKPDBLQPY-UHFFFAOYSA-N 3-(3,4-dihydro-2h-pyran-6-yl)benzonitrile Chemical compound N#CC1=CC=CC(C=2OCCCC=2)=C1 OSKOSPKPDBLQPY-UHFFFAOYSA-N 0.000 description 2
- IJWHBFPEDCWRMT-UHFFFAOYSA-N 3-(oxan-2-yl)benzonitrile Chemical compound N#CC1=CC=CC(C2OCCCC2)=C1 IJWHBFPEDCWRMT-UHFFFAOYSA-N 0.000 description 2
- LAZRGYZYBRYGBR-UHFFFAOYSA-N 3-amino-1-[[1-(5-tert-butyl-1,3-oxazol-2-yl)cyclopropyl]amino]-4-(3,5-difluorophenyl)butan-2-ol Chemical compound O1C(C(C)(C)C)=CN=C1C1(NCC(O)C(N)CC=2C=C(F)C=C(F)C=2)CC1 LAZRGYZYBRYGBR-UHFFFAOYSA-N 0.000 description 2
- FDIHXBYYQCPWDX-UHFFFAOYSA-N 3-ethenylbenzonitrile Chemical compound C=CC1=CC=CC(C#N)=C1 FDIHXBYYQCPWDX-UHFFFAOYSA-N 0.000 description 2
- OQRDPCPTEDSJHU-UHFFFAOYSA-N 3-morpholin-4-ylbenzonitrile Chemical compound N#CC1=CC=CC(N2CCOCC2)=C1 OQRDPCPTEDSJHU-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 206010059245 Angiopathy Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 description 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- 208000031124 Dementia Alzheimer type Diseases 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 108090000783 Renin Proteins 0.000 description 2
- 102100028255 Renin Human genes 0.000 description 2
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical class [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- UAYWVJHJZHQCIE-UHFFFAOYSA-L Zinc iodide Inorganic materials I[Zn]I UAYWVJHJZHQCIE-UHFFFAOYSA-L 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 2
- 125000005336 allyloxy group Chemical group 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 125000003435 aroyl group Chemical group 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000004600 benzothiopyranyl group Chemical group S1C(C=CC2=C1C=CC=C2)* 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- WYXUZTXCGKPAEH-UHFFFAOYSA-N bromoethane;magnesium Chemical compound [Mg].CCBr WYXUZTXCGKPAEH-UHFFFAOYSA-N 0.000 description 2
- XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Chemical compound [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 2
- 125000001589 carboacyl group Chemical group 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- XWAIAVWHZJNZQQ-UHFFFAOYSA-N donepezil hydrochloride Chemical compound [H+].[Cl-].O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 XWAIAVWHZJNZQQ-UHFFFAOYSA-N 0.000 description 2
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 238000002875 fluorescence polarization Methods 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 125000004475 heteroaralkyl group Chemical group 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 239000004030 hiv protease inhibitor Substances 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 2
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- OTCKOJUMXQWKQG-UHFFFAOYSA-L magnesium bromide Chemical compound [Mg+2].[Br-].[Br-] OTCKOJUMXQWKQG-UHFFFAOYSA-L 0.000 description 2
- 229910001623 magnesium bromide Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 2
- 230000006386 memory function Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- UMCYJYYTVUBBRU-UHFFFAOYSA-N methyl 2-(3-cyanophenyl)-2-methylpropanoate Chemical compound COC(=O)C(C)(C)C1=CC=CC(C#N)=C1 UMCYJYYTVUBBRU-UHFFFAOYSA-N 0.000 description 2
- BHIWKHZACMWKOJ-UHFFFAOYSA-N methyl isobutyrate Chemical compound COC(=O)C(C)C BHIWKHZACMWKOJ-UHFFFAOYSA-N 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- 208000027061 mild cognitive impairment Diseases 0.000 description 2
- VCDKGTQSKNBZMM-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-3-hydroxy-4-[[1-(4-methylpentyl)cyclopropyl]amino]butan-2-yl]acetamide Chemical compound C=1C(F)=CC(F)=CC=1CC(NC(C)=O)C(O)CNC1(CCCC(C)C)CC1 VCDKGTQSKNBZMM-UHFFFAOYSA-N 0.000 description 2
- KDSLZYKVISFOTP-UHFFFAOYSA-N n-[4-[[1-(5-tert-butyl-1,3-oxazol-2-yl)cyclopropyl]amino]-1-(3,5-difluorophenyl)-3-hydroxybutan-2-yl]acetamide Chemical compound C1CC1(C=1OC(=CN=1)C(C)(C)C)NCC(O)C(NC(=O)C)CC1=CC(F)=CC(F)=C1 KDSLZYKVISFOTP-UHFFFAOYSA-N 0.000 description 2
- XBXCNNQPRYLIDE-UHFFFAOYSA-M n-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 description 2
- 239000007922 nasal spray Substances 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 150000002924 oxiranes Chemical class 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Chemical group 0.000 description 2
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000007310 pathophysiology Effects 0.000 description 2
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 125000006308 propyl amino group Chemical group 0.000 description 2
- 230000006337 proteolytic cleavage Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- 239000012898 sample dilution Substances 0.000 description 2
- 208000008864 scrapie Diseases 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 235000010265 sodium sulphite Nutrition 0.000 description 2
- 239000007892 solid unit dosage form Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- KYZOOBJWCDUVSY-UHFFFAOYSA-N tert-butyl n-[1-[(3,3-dimethyl-2-oxobutyl)carbamoyl]cyclopropyl]carbamate Chemical compound CC(C)(C)C(=O)CNC(=O)C1(NC(=O)OC(C)(C)C)CC1 KYZOOBJWCDUVSY-UHFFFAOYSA-N 0.000 description 2
- NKGKCDXMOMAORK-UHFFFAOYSA-N tert-butyl n-[2-(3,5-difluorophenyl)-1-(oxiran-2-yl)ethyl]carbamate Chemical compound C1OC1C(NC(=O)OC(C)(C)C)CC1=CC(F)=CC(F)=C1 NKGKCDXMOMAORK-UHFFFAOYSA-N 0.000 description 2
- ISTGQSQWSKCNFJ-UHFFFAOYSA-N tert-butyl n-ethylcarbamate Chemical compound CCNC(=O)OC(C)(C)C ISTGQSQWSKCNFJ-UHFFFAOYSA-N 0.000 description 2
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000011820 transgenic animal model Methods 0.000 description 2
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 125000004933 β-carbolinyl group Chemical group C1(=NC=CC=2C3=CC=CC=C3NC12)* 0.000 description 2
- DIQOUXNTSMWQSA-WHFBIAKZSA-N (1s,4s)-2-oxa-5-azabicyclo[2.2.1]heptane Chemical compound C1O[C@]2([H])CN[C@@]1([H])C2 DIQOUXNTSMWQSA-WHFBIAKZSA-N 0.000 description 1
- XDBHWPLGGBLUHH-UHFFFAOYSA-N (3-cyanophenyl)boronic acid Chemical compound OB(O)C1=CC=CC(C#N)=C1 XDBHWPLGGBLUHH-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- FSVXWHPAMOPZCT-UHFFFAOYSA-N 1,1'-biphenyl;ditert-butylphosphane Chemical group CC(C)(C)PC(C)(C)C.C1=CC=CC=C1C1=CC=CC=C1 FSVXWHPAMOPZCT-UHFFFAOYSA-N 0.000 description 1
- RBACIKXCRWGCBB-UHFFFAOYSA-N 1,2-Epoxybutane Chemical compound CCC1CO1 RBACIKXCRWGCBB-UHFFFAOYSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- YUCBLVFHJWOYDN-HVLQGHBFSA-N 1,4-bis[(s)-[(2r,4s,5r)-5-ethyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methoxy]phthalazine Chemical compound C1=C(OC)C=C2C([C@H](OC=3C4=CC=CC=C4C(O[C@H]([C@@H]4N5CC[C@H]([C@H](C5)CC)C4)C=4C5=CC(OC)=CC=C5N=CC=4)=NN=3)[C@H]3C[C@@H]4CCN3C[C@@H]4CC)=CC=NC2=C1 YUCBLVFHJWOYDN-HVLQGHBFSA-N 0.000 description 1
- GZGPRZYZKBQPBQ-UHFFFAOYSA-N 1,4-dioxaspiro[4.5]decane Chemical compound O1CCOC11CCCCC1 GZGPRZYZKBQPBQ-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- DSKCOVBHIFAJRI-UHFFFAOYSA-N 1-[(2-methylpropan-2-yl)oxycarbonylamino]cyclopropane-1-carboxylic acid Chemical compound CC(C)(C)OC(=O)NC1(C(O)=O)CC1 DSKCOVBHIFAJRI-UHFFFAOYSA-N 0.000 description 1
- YBOXLMQAQNDOQY-UHFFFAOYSA-N 1-[3-(2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)phenyl]cyclopropan-1-amine Chemical compound C=1C=CC(N2C3CC(OC3)C2)=CC=1C1(N)CC1 YBOXLMQAQNDOQY-UHFFFAOYSA-N 0.000 description 1
- CRTRUQUJSMFWPD-UHFFFAOYSA-N 1-amino-3,3-dimethylbutan-2-one Chemical compound CC(C)(C)C(=O)CN CRTRUQUJSMFWPD-UHFFFAOYSA-N 0.000 description 1
- YXZFFTJAHVMMLF-UHFFFAOYSA-N 1-bromo-3-methylbutane Chemical compound CC(C)CCBr YXZFFTJAHVMMLF-UHFFFAOYSA-N 0.000 description 1
- SNBOPCHPZHUDQZ-UHFFFAOYSA-N 1-bromo-3-methylbutane;magnesium Chemical compound [Mg].CC(C)CCBr SNBOPCHPZHUDQZ-UHFFFAOYSA-N 0.000 description 1
- 125000006083 1-bromoethyl group Chemical group 0.000 description 1
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 1
- 125000001088 1-naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- OYRBDGKUVUVWRI-UHFFFAOYSA-N 1-phenylcyclopropan-1-amine Chemical compound C=1C=CC=CC=1C1(N)CC1 OYRBDGKUVUVWRI-UHFFFAOYSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- UTQNKKSJPHTPBS-UHFFFAOYSA-N 2,2,2-trichloroethanone Chemical group ClC(Cl)(Cl)[C]=O UTQNKKSJPHTPBS-UHFFFAOYSA-N 0.000 description 1
- CFTOTSJVQRFXOF-UHFFFAOYSA-N 2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole Chemical compound N1C2=CC=CC=C2C2=C1CNCC2 CFTOTSJVQRFXOF-UHFFFAOYSA-N 0.000 description 1
- XKLNOVWDVMWTOB-UHFFFAOYSA-N 2,3,4,9-tetrahydro-1h-carbazole Chemical compound N1C2=CC=CC=C2C2=C1CCCC2 XKLNOVWDVMWTOB-UHFFFAOYSA-N 0.000 description 1
- MKEJZKKVVUZXIS-UHFFFAOYSA-N 2,4-dibromo-1,3-thiazole Chemical compound BrC1=CSC(Br)=N1 MKEJZKKVVUZXIS-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- MFGOFGRYDNHJTA-UHFFFAOYSA-N 2-amino-1-(2-fluorophenyl)ethanol Chemical compound NCC(O)C1=CC=CC=C1F MFGOFGRYDNHJTA-UHFFFAOYSA-N 0.000 description 1
- 229940058020 2-amino-2-methyl-1-propanol Drugs 0.000 description 1
- QKBKGNDTLQFSEU-UHFFFAOYSA-N 2-bromo-3,3,3-trifluoroprop-1-ene Chemical compound FC(F)(F)C(Br)=C QKBKGNDTLQFSEU-UHFFFAOYSA-N 0.000 description 1
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000001216 2-naphthoyl group Chemical group C1=C(C=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- TZRUKFFDSQQSCK-UHFFFAOYSA-N 2-pent-4-ynoxyoxane Chemical compound C#CCCCOC1CCCCO1 TZRUKFFDSQQSCK-UHFFFAOYSA-N 0.000 description 1
- LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical group NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- JLTQQUZULAIGMF-UHFFFAOYSA-N 3-amino-1-[[1-[3-(1,1-difluoro-2-methylpropan-2-yl)phenyl]cyclopropyl]amino]-4-(3,5-difluorophenyl)butan-2-ol Chemical compound FC(F)C(C)(C)C1=CC=CC(C2(CC2)NCC(O)C(N)CC=2C=C(F)C=C(F)C=2)=C1 JLTQQUZULAIGMF-UHFFFAOYSA-N 0.000 description 1
- KFPOAWPAAVJLAU-UHFFFAOYSA-N 3-amino-4-(3,5-difluorophenyl)-1-[[1-[3-(1,3-dioxepan-5-yl)phenyl]cyclopropyl]amino]butan-2-ol Chemical compound C1CC1(C=1C=C(C=CC=1)C1COCOCC1)NCC(O)C(N)CC1=CC(F)=CC(F)=C1 KFPOAWPAAVJLAU-UHFFFAOYSA-N 0.000 description 1
- FQWSWXFWPYVXAW-UHFFFAOYSA-N 3-amino-4-(3,5-difluorophenyl)-1-[[1-[3-(1,3-dioxolan-4-yl)phenyl]cyclopropyl]amino]butan-2-ol Chemical compound C1CC1(C=1C=C(C=CC=1)C1OCOC1)NCC(O)C(N)CC1=CC(F)=CC(F)=C1 FQWSWXFWPYVXAW-UHFFFAOYSA-N 0.000 description 1
- AKZPHOHJMSZHHT-UHFFFAOYSA-N 3-amino-4-(3,5-difluorophenyl)-1-[[1-[3-(2-methyloxolan-2-yl)phenyl]cyclopropyl]amino]butan-2-ol Chemical compound C=1C=CC(C2(CC2)NCC(O)C(N)CC=2C=C(F)C=C(F)C=2)=CC=1C1(C)CCCO1 AKZPHOHJMSZHHT-UHFFFAOYSA-N 0.000 description 1
- WIWZUWDSAOXXFL-UHFFFAOYSA-N 3-amino-4-(3,5-difluorophenyl)-1-[[1-[3-(oxolan-2-yl)phenyl]cyclopropyl]amino]butan-2-ol Chemical compound C1CC1(C=1C=C(C=CC=1)C1OCCC1)NCC(O)C(N)CC1=CC(F)=CC(F)=C1 WIWZUWDSAOXXFL-UHFFFAOYSA-N 0.000 description 1
- FESQIVQGNFPKHU-UHFFFAOYSA-N 3-amino-4-(3,5-difluorophenyl)-1-[[1-[3-(oxolan-3-yl)phenyl]cyclopropyl]amino]butan-2-ol Chemical compound C1CC1(C=1C=C(C=CC=1)C1COCC1)NCC(O)C(N)CC1=CC(F)=CC(F)=C1 FESQIVQGNFPKHU-UHFFFAOYSA-N 0.000 description 1
- XSRLYBGHWGLTSS-UHFFFAOYSA-N 3-amino-4-(3,5-difluorophenyl)-1-[[1-[4-(2,2-dimethylpropyl)-1,3-thiazol-2-yl]cyclopropyl]amino]butan-2-ol Chemical compound CC(C)(C)CC1=CSC(C2(CC2)NCC(O)C(N)CC=2C=C(F)C=C(F)C=2)=N1 XSRLYBGHWGLTSS-UHFFFAOYSA-N 0.000 description 1
- KXOYEMBQCMUTOL-UHFFFAOYSA-N 3-bromo-5-(1-methylimidazol-2-yl)-1,2,4-thiadiazole Chemical group CN1C=CN=C1C1=NC(Br)=NS1 KXOYEMBQCMUTOL-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-M 3-carboxynaphthalen-2-olate Chemical compound C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-M 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- PMATZTZNYRCHOR-IMVLJIQESA-N 30-ethyl-33-[(e)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone Chemical compound CCC1NC(=O)C(C(O)C(C)C\C=C\C)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-IMVLJIQESA-N 0.000 description 1
- BAKUAUDFCNFLBX-UHFFFAOYSA-N 4,7-dihydro-1,3-dioxepine Chemical compound C1OCC=CCO1 BAKUAUDFCNFLBX-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- HVBSAKJJOYLTQU-UHFFFAOYSA-M 4-aminobenzenesulfonate Chemical class NC1=CC=C(S([O-])(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-M 0.000 description 1
- VDTIGYKLTROQAH-UHFFFAOYSA-N 4-bromo-1,3-thiazole Chemical compound BrC1=CSC=N1 VDTIGYKLTROQAH-UHFFFAOYSA-N 0.000 description 1
- 125000000242 4-chlorobenzoyl group Chemical group ClC1=CC=C(C(=O)*)C=C1 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- FIEKVYPYFQSFTP-UHFFFAOYSA-N 6-methyl-7-oxabicyclo[4.1.0]heptane Chemical compound C1CCCC2OC21C FIEKVYPYFQSFTP-UHFFFAOYSA-N 0.000 description 1
- FYZDPIIMSZAKGP-UHFFFAOYSA-N 9-bromo-9-borabicyclo[3.3.1]nonane Chemical compound C1CCC2CCCC1B2Br FYZDPIIMSZAKGP-UHFFFAOYSA-N 0.000 description 1
- 208000024667 ABeta amyloidosis, Dutch type Diseases 0.000 description 1
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 230000007082 Aβ accumulation Effects 0.000 description 1
- 230000007351 Aβ plaque formation Effects 0.000 description 1
- 101100112002 Bacillus subtilis (strain 168) catE gene Proteins 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- MNCZFZJFVNLIBJ-UHFFFAOYSA-N CC(C)(C)OC(NC(Cc1cc(F)cc(F)c1)C(CN)O)=O Chemical compound CC(C)(C)OC(NC(Cc1cc(F)cc(F)c1)C(CN)O)=O MNCZFZJFVNLIBJ-UHFFFAOYSA-N 0.000 description 1
- HICAEOGCRFLJFZ-UHFFFAOYSA-N CC(NC(Cc1cc(F)cc(F)c1)C(CNCc1cccc(-[n]2nccc2)c1)O)=O Chemical compound CC(NC(Cc1cc(F)cc(F)c1)C(CNCc1cccc(-[n]2nccc2)c1)O)=O HICAEOGCRFLJFZ-UHFFFAOYSA-N 0.000 description 1
- XJWBEDKLESTWJI-UHFFFAOYSA-N CC(NCC(C(Cc1cc(F)cc(F)c1)NC(OC(C)(C)C)=O)O)O Chemical compound CC(NCC(C(Cc1cc(F)cc(F)c1)NC(OC(C)(C)C)=O)O)O XJWBEDKLESTWJI-UHFFFAOYSA-N 0.000 description 1
- YUXSKEMGSIDZQR-ARJAWSKDSA-N CC/C=C\CC(C#N)O Chemical compound CC/C=C\CC(C#N)O YUXSKEMGSIDZQR-ARJAWSKDSA-N 0.000 description 1
- IRTCJFCIQKNFPP-UHFFFAOYSA-N CC1OCCOC1 Chemical compound CC1OCCOC1 IRTCJFCIQKNFPP-UHFFFAOYSA-N 0.000 description 1
- CTQKNKHSGCHLBY-UHFFFAOYSA-N CCC(C1)C1(C1=CCCC([n]2nccc2)=C1)NCC(C(Cc1cc(F)cc(F)c1)NC(C)=[N]=C)O Chemical compound CCC(C1)C1(C1=CCCC([n]2nccc2)=C1)NCC(C(Cc1cc(F)cc(F)c1)NC(C)=[N]=C)O CTQKNKHSGCHLBY-UHFFFAOYSA-N 0.000 description 1
- KPQRRSZOIWQTOC-UHFFFAOYSA-N CCC(C1)C1(c1cccc(N2NCC=C2)c1)NCC(C(Cc1cc(F)cc(F)c1)NC(C)=O)O Chemical compound CCC(C1)C1(c1cccc(N2NCC=C2)c1)NCC(C(Cc1cc(F)cc(F)c1)NC(C)=O)O KPQRRSZOIWQTOC-UHFFFAOYSA-N 0.000 description 1
- NRSKLCCINAQQQL-UHFFFAOYSA-N CCN(CC)S.F.F.F Chemical compound CCN(CC)S.F.F.F NRSKLCCINAQQQL-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000003908 Cathepsin D Human genes 0.000 description 1
- 108090000258 Cathepsin D Proteins 0.000 description 1
- 102000004178 Cathepsin E Human genes 0.000 description 1
- 108090000611 Cathepsin E Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical class OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical compound CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 238000011771 FVB mouse Methods 0.000 description 1
- 208000034846 Familial Amyloid Neuropathies Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 229940125373 Gamma-Secretase Inhibitor Drugs 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 108010010369 HIV Protease Proteins 0.000 description 1
- 229940122440 HIV protease inhibitor Drugs 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 206010019889 Hereditary neuropathic amyloidosis Diseases 0.000 description 1
- 101000823051 Homo sapiens Amyloid-beta precursor protein Proteins 0.000 description 1
- GIXSGYBTGHLHTM-UHFFFAOYSA-N ICC1=CC=[I]C=C1 Chemical compound ICC1=CC=[I]C=C1 GIXSGYBTGHLHTM-UHFFFAOYSA-N 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- YWZKZHCZKIKAAC-UHFFFAOYSA-N NCc1cccc(-[n]2nccc2)c1 Chemical compound NCc1cccc(-[n]2nccc2)c1 YWZKZHCZKIKAAC-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 101710138657 Neurotoxin Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 101150003085 Pdcl gene Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 208000024777 Prion disease Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical class CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- YJDYDFNKCBANTM-QCWCSKBGSA-N SDZ PSC 833 Chemical compound C\C=C\C[C@@H](C)C(=O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](C(C)C)NC1=O YJDYDFNKCBANTM-QCWCSKBGSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 229920002253 Tannate Chemical class 0.000 description 1
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 229920004896 Triton X-405 Polymers 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000000641 acridinyl group Chemical class C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000003942 amyloidogenic effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940027998 antiseptic and disinfectant acridine derivative Drugs 0.000 description 1
- 101150031224 app gene Proteins 0.000 description 1
- 229940039856 aricept Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960002430 atomoxetine Drugs 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 1
- 150000001607 bioavailable molecules Chemical class 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- CGVWPQOFHSAKRR-NDEPHWFRSA-N biricodar Chemical compound COC1=C(OC)C(OC)=CC(C(=O)C(=O)N2[C@@H](CCCC2)C(=O)OC(CCCC=2C=NC=CC=2)CCCC=2C=NC=CC=2)=C1 CGVWPQOFHSAKRR-NDEPHWFRSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- QCIGLPLDNRDLQQ-UHFFFAOYSA-N butan-2-ylcarbamic acid Chemical compound CCC(C)NC(O)=O QCIGLPLDNRDLQQ-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000004900 c-terminal fragment Anatomy 0.000 description 1
- HUCVOHYBFXVBRW-UHFFFAOYSA-M caesium hydroxide Inorganic materials [OH-].[Cs+] HUCVOHYBFXVBRW-UHFFFAOYSA-M 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 238000000114 cell free in vitro assay Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- 125000002668 chloroacetyl group Chemical group ClCC(=O)* 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 125000004617 chromonyl group Chemical group O1C(=CC(C2=CC=CC=C12)=O)* 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 231100000870 cognitive problem Toxicity 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 125000000332 coumarinyl group Chemical group O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000004802 cyanophenyl group Chemical group 0.000 description 1
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- ZWAJLVLEBYIOTI-UHFFFAOYSA-N cyclohexene oxide Chemical compound C1CCCC2OC21 ZWAJLVLEBYIOTI-UHFFFAOYSA-N 0.000 description 1
- 125000006639 cyclohexyl carbonyl group Chemical group 0.000 description 1
- WVIIMZNLDWSIRH-UHFFFAOYSA-N cyclohexylcyclohexane Chemical group C1CCCCC1C1CCCCC1 WVIIMZNLDWSIRH-UHFFFAOYSA-N 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical class OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 125000006255 cyclopropyl carbonyl group Chemical group [H]C1([H])C([H])([H])C1([H])C(*)=O 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000005993 dihydrobenzisoxazinyl group Chemical group 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005045 dihydroisoquinolinyl group Chemical group C1(NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000005046 dihydronaphthyl group Chemical group 0.000 description 1
- 125000005051 dihydropyrazinyl group Chemical group N1(CC=NC=C1)* 0.000 description 1
- 125000005052 dihydropyrazolyl group Chemical group N1(NCC=C1)* 0.000 description 1
- 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 125000005053 dihydropyrimidinyl group Chemical group N1(CN=CC=C1)* 0.000 description 1
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 1
- 125000005044 dihydroquinolinyl group Chemical group N1(CC=CC2=CC=CC=C12)* 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- NKDDWNXOKDWJAK-UHFFFAOYSA-N dimethoxymethane Chemical compound COCOC NKDDWNXOKDWJAK-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Natural products O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 1
- 229960003135 donepezil hydrochloride Drugs 0.000 description 1
- 208000036536 dutch type ABeta amyloidosis Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- UTUVIKZNQWNGIM-UHFFFAOYSA-N ethyl 2-phenylpropanoate Chemical compound CCOC(=O)C(C)C1=CC=CC=C1 UTUVIKZNQWNGIM-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229940108366 exelon Drugs 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 125000001207 fluorophenyl group Chemical group 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000008369 fruit flavor Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229930184727 ginkgolide Natural products 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002306 glutamic acid derivatives Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 150000003840 hydrochlorides Chemical group 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- RCCPEORTSYDPMB-UHFFFAOYSA-N hydroxy benzenecarboximidothioate Chemical compound OSC(=N)C1=CC=CC=C1 RCCPEORTSYDPMB-UHFFFAOYSA-N 0.000 description 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- LPAGFVYQRIESJQ-UHFFFAOYSA-N indoline Chemical compound C1=CC=C2NCCC2=C1 LPAGFVYQRIESJQ-UHFFFAOYSA-N 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 208000021005 inheritance pattern Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000005994 isobenzotetrahydrofuranyl group Chemical group 0.000 description 1
- 125000005995 isobenzotetrahydrothienyl group Chemical group 0.000 description 1
- 125000005990 isobenzothienyl group Chemical group 0.000 description 1
- WDAXFOBOLVPGLV-UHFFFAOYSA-N isobutyric acid ethyl ester Natural products CCOC(=O)C(C)C WDAXFOBOLVPGLV-UHFFFAOYSA-N 0.000 description 1
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
- 125000003151 isocoumarinyl group Chemical group C1(=O)OC(=CC2=CC=CC=C12)* 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004558 lewy body Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- DLBFLQKQABVKGT-UHFFFAOYSA-L lucifer yellow dye Chemical compound [Li+].[Li+].[O-]S(=O)(=O)C1=CC(C(N(C(=O)NN)C2=O)=O)=C3C2=CC(S([O-])(=O)=O)=CC3=C1N DLBFLQKQABVKGT-UHFFFAOYSA-L 0.000 description 1
- 150000002680 magnesium Chemical class 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- QUXHCILOWRXCEO-UHFFFAOYSA-M magnesium;butane;chloride Chemical compound [Mg+2].[Cl-].CCC[CH2-] QUXHCILOWRXCEO-UHFFFAOYSA-M 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- LRMHVVPPGGOAJQ-UHFFFAOYSA-N methyl nitrate Chemical compound CO[N+]([O-])=O LRMHVVPPGGOAJQ-UHFFFAOYSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- GSCCNLSKRQVMJD-UHFFFAOYSA-N n-[2-[[4-[2-(6,7-dimethyl-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenyl]carbamoyl]-4,5-dimethylphenyl]quinoline-3-carboxamide Chemical compound C1=CC=CC2=CC(C(=O)NC3=CC(C)=C(C)C=C3C(=O)NC3=CC=C(C=C3)CCN3CCC=4C=C(C(=CC=4C3)C)C)=CN=C21 GSCCNLSKRQVMJD-UHFFFAOYSA-N 0.000 description 1
- OSFCMRGOZNQUSW-UHFFFAOYSA-N n-[4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenyl]-5-methoxy-9-oxo-10h-acridine-4-carboxamide Chemical compound N1C2=C(OC)C=CC=C2C(=O)C2=C1C(C(=O)NC1=CC=C(C=C1)CCN1CCC=3C=C(C(=CC=3C1)OC)OC)=CC=C2 OSFCMRGOZNQUSW-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002159 nanocrystal Substances 0.000 description 1
- 125000001038 naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 125000003884 phenylalkyl group Chemical group 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical class [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- MICLTPPSCUXHJT-UHFFFAOYSA-M potassium;4-[3-(6-oxo-3h-purin-9-yl)propanoylamino]benzoate Chemical compound [K+].C1=CC(C(=O)[O-])=CC=C1NC(=O)CCN1C(NC=NC2=O)=C2N=C1 MICLTPPSCUXHJT-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 230000007026 protein scission Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 229960001404 quinidine Drugs 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000004620 quinolinyl-N-oxide group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical class OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- CTDQAGUNKPRERK-UHFFFAOYSA-N spirodecane Chemical compound C1CCCC21CCCCC2 CTDQAGUNKPRERK-UHFFFAOYSA-N 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 229940012488 strattera Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical class [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical class NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical class [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- NEFFYBLTTHTHRE-UHFFFAOYSA-N tert-butyl n-[1-(3,5-difluorophenyl)-4-[[1-[2-(2,2-dimethylpropyl)-1,3-thiazol-4-yl]cyclopropyl]amino]-3-hydroxybutan-2-yl]carbamate Chemical compound S1C(CC(C)(C)C)=NC(C2(CC2)NCC(O)C(CC=2C=C(F)C=C(F)C=2)NC(=O)OC(C)(C)C)=C1 NEFFYBLTTHTHRE-UHFFFAOYSA-N 0.000 description 1
- SOKVNNNOBLWBSY-UHFFFAOYSA-N tert-butyl n-[1-(3-bromophenyl)cyclopropyl]carbamate Chemical compound C=1C=CC(Br)=CC=1C1(NC(=O)OC(C)(C)C)CC1 SOKVNNNOBLWBSY-UHFFFAOYSA-N 0.000 description 1
- GMIIQBKTPGJOKV-UHFFFAOYSA-N tert-butyl n-[1-(3-pyrazol-1-ylphenyl)cyclopropyl]carbamate Chemical compound C=1C=CC(N2N=CC=C2)=CC=1C1(NC(=O)OC(C)(C)C)CC1 GMIIQBKTPGJOKV-UHFFFAOYSA-N 0.000 description 1
- LPRZACPBWAXTBB-UHFFFAOYSA-N tert-butyl n-[4-[[1-(5-tert-butyl-1,3-oxazol-2-yl)cyclopropyl]amino]-1-(3,5-difluorophenyl)-3-hydroxybutan-2-yl]carbamate Chemical compound C1CC1(C=1OC(=CN=1)C(C)(C)C)NCC(O)C(NC(=O)OC(C)(C)C)CC1=CC(F)=CC(F)=C1 LPRZACPBWAXTBB-UHFFFAOYSA-N 0.000 description 1
- ZXLDQJLIBNPEFJ-UHFFFAOYSA-N tetrahydro-beta-carboline Natural products C1CNC(C)C2=C1C1=CC=C(OC)C=C1N2 ZXLDQJLIBNPEFJ-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical group C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 201000007905 transthyretin amyloidosis Diseases 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- QIWRFOJWQSSRJZ-UHFFFAOYSA-N tributyl(ethenyl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C=C QIWRFOJWQSSRJZ-UHFFFAOYSA-N 0.000 description 1
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 1
- BYGOPQKDHGXNCD-UHFFFAOYSA-N tripotassium;iron(3+);hexacyanide Chemical compound [K+].[K+].[K+].[Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] BYGOPQKDHGXNCD-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229950010938 valspodar Drugs 0.000 description 1
- 108010082372 valspodar Proteins 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000000264 venule Anatomy 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- IHOVFYSQUDPMCN-QKUIIBHLSA-N zosuquidar Chemical compound C([C@H](COC=1C2=CC=CN=C2C=CC=1)O)N(CC1)CCN1C1C2=CC=CC=C2C2C(F)(F)C2C2=CC=CC=C12 IHOVFYSQUDPMCN-QKUIIBHLSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/36—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/06—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D309/06—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/12—1,4-Dioxanes; Hydrogenated 1,4-dioxanes not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D321/00—Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups C07D317/00 - C07D319/00
- C07D321/02—Seven-membered rings
- C07D321/04—Seven-membered rings not condensed with other rings
- C07D321/06—1,3-Dioxepines; Hydrogenated 1,3-dioxepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/14—All rings being cycloaliphatic
- C07C2602/18—All rings being cycloaliphatic the ring system containing six carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
- C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrane Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Furan Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72527805P | 2005-10-12 | 2005-10-12 | |
| US75619206P | 2006-01-05 | 2006-01-05 | |
| US79515506P | 2006-04-27 | 2006-04-27 | |
| PCT/US2006/039725 WO2007047306A1 (en) | 2005-10-12 | 2006-10-11 | Methods of treating amyloidosis using aryl-cyclopropyl derivative aspartyl protease inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009511589A true JP2009511589A (ja) | 2009-03-19 |
| JP2009511589A5 JP2009511589A5 (enExample) | 2010-01-21 |
Family
ID=37734282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008535650A Withdrawn JP2009511589A (ja) | 2005-10-12 | 2006-10-11 | アリール−シクロプロピル誘導体のアスパルチルプロテアーゼ阻害剤を使用してアミロイドーシスを治療する方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20070149525A1 (enExample) |
| EP (1) | EP1937638A1 (enExample) |
| JP (1) | JP2009511589A (enExample) |
| CA (1) | CA2624904A1 (enExample) |
| WO (1) | WO2007047306A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| AU2008236679B2 (en) | 2007-04-03 | 2013-11-28 | Fmc Corporation | Substituted benzene fungicides |
| WO2009038412A2 (en) * | 2007-09-21 | 2009-03-26 | Lg Life Sciences, Ltd. | Beta-secretase inhibiting compounds |
| KR20090031331A (ko) * | 2007-09-21 | 2009-03-25 | 주식회사 엘지생명과학 | 옥소 디하이드로 피라졸을 포함하는 신규한 베타 세크리타제 저해용 화합물 |
| WO2011138285A1 (de) | 2010-05-05 | 2011-11-10 | Bayer Cropscience Ag | Thiazolderivate als schädlingsbekämpfungsmittel |
| WO2013059215A1 (en) | 2011-10-17 | 2013-04-25 | Biotheryx, Inc. | Substituted biaryl alkyl amides |
| US9493485B2 (en) | 2012-03-20 | 2016-11-15 | Imago Pharmaceuticals, Inc. | Spirocyclic dihydro-thiazine and dihydro-oxazine BACE inhibitors, and compositions and uses thereof |
| CN104151160A (zh) * | 2013-05-15 | 2014-11-19 | 重庆华邦制药有限公司 | 用酯类化合物合成2-甲基丙酸酯衍生物的方法 |
| EP3915983A1 (en) * | 2020-05-26 | 2021-12-01 | Centre National de la Recherche Scientifique | Pyridine-thiazole-oxime and pyridine-oxazole-oxime derivatives as reactivators of organophosphorous nerve agent (opna)-inhibited human acetylcholinesterase for the treatment of nervous and/or respiratory failure after intoxication with opna |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) * | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| FI902006A7 (fi) * | 1987-10-21 | 1990-04-20 | Upjohn Co | Menetelmä renniini-inhibiittoreiden valmistamiseksi, jotka sisältävät 1-amino-2-hydroksi-2-heterosyklisen etyylitähteen |
| US5254595A (en) * | 1988-12-23 | 1993-10-19 | Elf Sanofi | Aryloxypropanolaminotetralins, a process for their preparation and pharmaceutical compositions containing them |
| DE4004820A1 (de) * | 1989-08-05 | 1991-04-25 | Bayer Ag | Renininhibitoren, verfahren zur herstellung und ihre verwendung in arzneimitteln |
| US5696270A (en) * | 1989-05-23 | 1997-12-09 | Abbott Laboratories | Intermediate for making retroviral protease inhibiting compounds |
| US5362912A (en) * | 1989-05-23 | 1994-11-08 | Abbott Laboratories | Process for the preparation of a substituted diaminodiol |
| JPH06507782A (ja) * | 1990-06-15 | 1994-09-08 | サイオス ノバ インコーポレイテッド | アルツハイマー病のアミロイド形成開症状を示すヒト以外の組換え哺乳動物 |
| US5912410A (en) * | 1990-06-15 | 1999-06-15 | Scios Inc. | Transgenic non-human mice displaying the amyloid-forming pathology of alzheimer's disease |
| AU652997B2 (en) * | 1991-01-21 | 1994-09-15 | Elan Pharmaceuticals, Inc. | Test and model for alzheimer's disease |
| US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| DE69233109T2 (de) * | 1992-01-07 | 2004-05-19 | Elan Pharmaceuticals, Inc., San Francisco | Transgene tiermodelle fur alzheimer-krankheit |
| US5604102A (en) * | 1992-04-15 | 1997-02-18 | Athena Neurosciences, Inc. | Methods of screening for β-amyloid peptide production inhibitors |
| US5441870A (en) * | 1992-04-15 | 1995-08-15 | Athena Neurosciences, Inc. | Methods for monitoring cellular processing of β-amyloid precursor protein |
| US5766846A (en) * | 1992-07-10 | 1998-06-16 | Athena Neurosciences | Methods of screening for compounds which inhibit soluble β-amyloid peptide production |
| DE69334250D1 (de) * | 1992-12-29 | 2009-01-29 | Abbott Lab | Verfahren und Intermediate zur Herstellung von retroviralen Proteasehemmern |
| AU702293B2 (en) * | 1993-10-27 | 1999-02-18 | Athena Neurosciences, Inc. | Transgenic animals harboring APP allele having Swedish mutation |
| US5877399A (en) * | 1994-01-27 | 1999-03-02 | Johns Hopkins University | Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease |
| US5744346A (en) * | 1995-06-07 | 1998-04-28 | Athena Neurosciences, Inc. | β-secretase |
| JPH11507538A (ja) * | 1995-06-07 | 1999-07-06 | アテナ ニューロサイエンシズ インコーポレイティド | β−セクレターゼ、β−セクレターゼに対する抗体、及びβ−セクレターゼ阻害を検出するためのアッセイ |
| US6191166B1 (en) * | 1997-11-21 | 2001-02-20 | Elan Pharmaceuticals, Inc. | Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis |
| US6045829A (en) * | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
| US6379666B1 (en) * | 1999-02-24 | 2002-04-30 | Edward L. Tobinick | TNF inhibitors for the treatment of neurological, retinal and muscular disorders |
| AU2001252958A1 (en) * | 2000-03-23 | 2001-10-03 | Elan Pharmaceuticals, Inc. | Compounds and methods to treat alzheimer's disease |
| US20030096864A1 (en) * | 2000-06-30 | 2003-05-22 | Fang Lawrence Y. | Compounds to treat alzheimer's disease |
| WO2003050073A1 (en) * | 2001-12-06 | 2003-06-19 | Elan Pharmaceuticals, Inc. | Substituted hydroxyethylamines |
| UY27967A1 (es) * | 2002-09-10 | 2004-05-31 | Pfizer | Acetil 2-hindroxi-1,3-diaminoalcanos |
| DE60329316D1 (de) * | 2002-11-12 | 2009-10-29 | Merck & Co Inc | Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer |
| PE20040762A1 (es) * | 2002-11-27 | 2004-11-06 | Elan Pharm Inc | Ureas substituidas y carbamatos utiles para el tratamiento de la enfermedad de alzheimer |
| TW200512195A (en) * | 2003-04-21 | 2005-04-01 | Elan Pharm Inc | Benzamide 2-hydroxy-3-diaminoalkanes |
| CN1863770B (zh) * | 2003-08-08 | 2011-05-25 | 先灵公司 | 具有杂环取代基的环胺base-1抑制剂 |
| CA2534950A1 (en) * | 2003-08-08 | 2005-02-24 | Schering Corporation | Cyclic amine bace-1 inhibitors having a benzamide substituent |
| EP1734961A2 (en) * | 2004-03-09 | 2006-12-27 | Elan Pharmaceuticals, Inc. | Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors |
| US20060014737A1 (en) * | 2004-03-09 | 2006-01-19 | Varghese John | Methods of treatment of amyloidosis using bi-aryl aspartyl protease inhibitors |
| WO2005095326A2 (en) * | 2004-03-25 | 2005-10-13 | Elan Pharmaceuticals, Inc. | 2-amino- and 2-thio-substituted 1,3-diaminopropanes |
| US7618978B2 (en) * | 2004-04-22 | 2009-11-17 | Eli Lilly And Company | Amides as BACE inhibitors |
| EP1773756A2 (en) * | 2004-07-09 | 2007-04-18 | Elan Pharmaceuticals, Inc. | Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors |
-
2006
- 2006-10-11 CA CA002624904A patent/CA2624904A1/en not_active Abandoned
- 2006-10-11 JP JP2008535650A patent/JP2009511589A/ja not_active Withdrawn
- 2006-10-11 EP EP06825760A patent/EP1937638A1/en not_active Withdrawn
- 2006-10-11 WO PCT/US2006/039725 patent/WO2007047306A1/en not_active Ceased
- 2006-10-12 US US11/546,347 patent/US20070149525A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007047306A1 (en) | 2007-04-26 |
| EP1937638A1 (en) | 2008-07-02 |
| CA2624904A1 (en) | 2007-04-26 |
| WO2007047306A8 (en) | 2007-12-27 |
| US20070149525A1 (en) | 2007-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7858642B2 (en) | Substituted hydroxyethylamine aspartyl protease inhibitors | |
| US20050239832A1 (en) | Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors | |
| US20090042961A1 (en) | Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors | |
| EP1729755A1 (en) | Methods of treatment of amyloidosis using aspartyl-protease inihibitors | |
| US20060014737A1 (en) | Methods of treatment of amyloidosis using bi-aryl aspartyl protease inhibitors | |
| US20050239790A1 (en) | Substituted hydroxyethylamine aspartyl protease inhibitors | |
| US20070149525A1 (en) | Methods of treating amyloidosis using aryl-cyclopropyl derivative aspartyl protease inhibitors | |
| US20050261273A1 (en) | Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors | |
| US7906556B2 (en) | Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors | |
| US20060128715A1 (en) | Oxime derivative hydroxyethylamine aspartyl-protease inhibitors | |
| US20080166332A1 (en) | Methods of Treatment of Amyloidosis Using Subsituted Ethanolcyclicamine Aspartyl Protease Inhibitors | |
| US20060074098A1 (en) | Methods of treatment of amyloidosis using ethanolcyclicamine aspartyl protease inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20091013 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091014 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091127 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20110513 |